NG-nitro-L-arginine prevents morphine tolerance

Eur J Pharmacol. 1992 Oct 20;221(2-3):399-400. doi: 10.1016/0014-2999(92)90732-j.


NMDA receptor antagonists, such as MK-801, prevent the development of tolerance to morphine. Since many NMDA actions involve the production of nitric oxide, we examined the effects of a nitric oxide synthase inhibitor on morphine tolerance. The analgesic response to morphine (5 mg/kg s.c.) given daily diminishes from 60% in naive animals to 0% within 5 days. Coadministration of NG-nitro-L-arginine (8 mg/kg per day) along with morphine prevents the demonstration of appreciable tolerance for at least 11 days. These results suggest that morphine tolerance involves the activation of NMDA receptors followed by the subsequent release of nitric oxide.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Arginine / analogs & derivatives*
  • Arginine / pharmacology
  • Drug Tolerance
  • Male
  • Mice
  • Morphine / pharmacology*
  • Nitric Oxide / metabolism
  • Nitroarginine
  • Receptors, N-Methyl-D-Aspartate / drug effects
  • Receptors, N-Methyl-D-Aspartate / physiology


  • Receptors, N-Methyl-D-Aspartate
  • Nitroarginine
  • Nitric Oxide
  • Morphine
  • Arginine